Abstract B174: The non-covalent HCK/BTK inhibitor TTX-114 displays potent <i>in vitro</i> and <i>in vivo</i> anti-tumor activity in leukemia and lymphoma
Ulrike Rauh(Centro de Pesquisas Oncológicas), Brian K. Hubbard(Broad Institute), Yoriko Saito(RIKEN Center for Integrative Medical Sciences), Takehiro Fukami(RIKEN Center for Integrative Medical Sciences), Eleonora Cannas(Institute of Oncology Research), Fumihiko Ishikawa(RIKEN Center for Integrative Medical Sciences), Nathalie Javidi‐Sharifi(Harvard University), Virendar K. Kaushik(Broad Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Ikuko Ogahara(RIKEN Center for Integrative Medical Sciences), Sabine Pilari, Michael H. Serrano‐Wu(Broad Institute), Franceso Bertoni(Institute of Oncology Research), Alberto J. Arribas(Institute of Oncology Research), Akiko Kaneko(RIKEN Center for Integrative Medical Sciences), Anthony Letai(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k